SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-237047
Filing Date
2021-08-05
Accepted
2021-08-05 08:06:04
Documents
13
Period of Report
2021-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d212527d8k.htm   iXBRL 8-K 25011
2 EX-99.1 d212527dex991.htm EX-99.1 67089
  Complete submission text file 0001193125-21-237047.txt   223787

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA akba-20210805.xsd EX-101.SCH 2914
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20210805_lab.xml EX-101.LAB 17372
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20210805_pre.xml EX-101.PRE 10967
6 EXTRACTED XBRL INSTANCE DOCUMENT d212527d8k_htm.xml XML 3236
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 211146420
SIC: 2834 Pharmaceutical Preparations